Podcasts about medicines

The rise of weight loss jabs could completely change the way people shop, and not just for food, according to a leading business consultancy. A new report by EY looks at the way GLP1 weight loss medicines are influencing consumer choices in Australia and what that could mean for business. Report co-author, Lisa Nijssen-Smith spoke to Lisa Owen.

Fluent Fiction - Hindi: A Moment of Misplaced Medicines: Trust and Hope Restored Find the full episode transcript, vocabulary words, and more:fluentfiction.com/hi/episode/2026-07-16-07-38-19-hi Story Transcript:Hi: गर्मियों का दिन था।En: It was a summer day.Hi: सूरज की तेज़ किरणें फ़ील्ड अस्पताल के ऊपर जल रही थीं।En: The intense rays of the sun were blazing over the field hospital.Hi: यह एक अस्थायी अस्पताल था, जिसमें तंबू लगे हुए थे और लोग बैचैन होकर इधर-उधर भागते नज़र आते थे।En: This was a temporary hospital, with tents set up, and people were seen anxiously running around.Hi: फ़ील्ड के किनारे खड़ा, डॉक्टर आरव एक खाली डिब्बे को देख रहा था।En: Standing at the edge of the field, Dr. Arav was looking at an empty box.Hi: उसकी आँखों में चिंता साफ़ झलक रही थी।En: Worry was clearly reflected in his eyes.Hi: अस्पताल में मरीजों की भीड़ बढ़ रही थी, और अचानक आयी हीटवेव के कारण हालात और गंभीर होते जा रहे थे।En: The crowd of patients in the hospital was increasing, and due to the sudden heatwave, the situation was becoming more serious.Hi: आरव ने गहरी सांस ली और मेहरा के पास गया।En: Arav took a deep breath and went to Mehra.Hi: मेहरा एक दयालु नर्स थी, जिसके चेहरे पर हमेशा मुस्कान रहती थी।En: Mehra was a kind nurse, who always had a smile on her face.Hi: वो आरव के प्रति अपने प्यार को गुप्त रखती थी, परंतु हर समय उसका सहयोग करती थी।En: She kept her love for Arav secret, but she always supported him.Hi: "मेहरा, दवाइयाँ गायब हैं," आरव ने चिंतित स्वर में कहा।En: "Mehra, the medicines are missing," Arav said in a concerned voice.Hi: "हमें यह समस्या हल करनी होगी।En: "We need to solve this problem."Hi: "मेहरा ने सहमति में सिर हिलाया, "हां, आरव।En: Mehra nodded in agreement, "Yes, Arav.Hi: हम किसी को भी इसे पता नहीं चलने देंगे।En: We won't let anyone find out about this."Hi: "इस बीच, राज ने, जो एक नया इंटर्न था, उनकी चर्चा सुनी।En: Meanwhile, Raj, who was a new intern, overheard their conversation.Hi: राज भले ही अनुभवहीन था, लेकिन उसकी आँखों में कुछ होशियारी झलकती थी।En: Although Raj was inexperienced, there was a certain cleverness in his eyes.Hi: वह भी इस गुप्त जांच का हिस्सा बनना चाहता था।En: He also wanted to be a part of this secret investigation.Hi: आरव ने पूरी योजना सुनायी।En: Arav explained the entire plan.Hi: सबको कमरा तटोलने और सबूत इकठ्ठा करने के लिए कहा गया।En: Everyone was told to search the room and gather evidence.Hi: रात होते ही अस्पताल शांत हो गया।En: As night fell, the hospital became quiet.Hi: पर आरव, मेहरा और राज चुपचाप अपनी योजना पर काम करते रहे।En: But Arav, Mehra, and Raj quietly continued to work on their plan.Hi: मेहरा ने अस्पताल की पर्चियाँ जांचीं, जबकि राज ने भंडारण कक्ष में चारों ओर देखा।En: Mehra checked the hospital sheets, while Raj looked around in the storage room.Hi: अचानक, राज के मुंह से एक हल्की सी चीख निकल गयी।En: Suddenly, a soft scream escaped from Raj.Hi: उसने एक कोने में कुछ बक्से छुपे देखे।En: He saw some boxes hidden in a corner.Hi: आरव और मेहरा जल्द ही वहां पहुँचे।En: Arav and Mehra quickly arrived there.Hi: आरव ने बक्से खोलना शुरू किया और पाया कि सभी दवाइयाँ उन्हीं में थीं।En: Arav started opening the boxes and found that all the medicines were in them.Hi: "राज!En: "Raj!Hi: ये कैसे हुआ?En: How did this happen?"Hi: " आरव ने थोड़ा कड़वे स्वर में पूछा।En: Arav asked in a slightly bitter tone.Hi: राज ने थोड़ी शर्मिंदगी में सिर झुका लिया।En: Raj hung his head in a bit of embarrassment.Hi: "सॉरी सर, मुझे लगा कि दवाइयाँ चोरी हो सकती हैं।En: "Sorry, sir, I thought the medicines might be stolen.Hi: इसलिए मैंने इन्हें यहाँ छिपा दिया।En: So, I hid them here."Hi: "आरव थोड़ी देर तक चुप रहे, फिर हँस पड़े।En: Arav remained silent for a while, then burst out laughing.Hi: "राज, मैं तुम्हारे इरादे समझ सकता हूँ, पर हमें जिम्मेदारी और समझदारी से काम करना होगा।En: "Raj, I can understand your intentions, but we have to work with responsibility and understanding."Hi: "वाकया समाप्त होने पर आरव ने धैर्य और समझदारी से राज के काम को सराहा और उसे सिखाया कि कैसे टीम के साथ विश्वास कायम रखना चाहिए।En: At the conclusion of the incident, Arav patiently and understandingly appreciated Raj's work and taught him how to build trust with the team.Hi: इस घटना ने न केवल आरव को अपने सहयोगियों के प्रति और सहनशील बनाया, बल्कि राज को भी समझदारी और परिपक्वता सिखाई।En: This incident not only made Arav more tolerant toward his colleagues but also taught Raj wisdom and maturity.Hi: जब सूरज की नई किरणें अस्पताल के तंबूओं पर पड़ीं, तो वहां उम्मीद की एक नई रोशनी थी।En: When the new rays of the sun fell on the hospital's tents, there was a new light of hope there. Vocabulary Words:intense: तेज़rays: किरणेंblazing: जल रहीtemporary: अस्थायीanxiously: बैचैनedge: किनारेreflected: झलक रहीsudden: अचानकheatwave: हीटवेवserious: गंभीरconcerned: चिंतितintern: इंटर्नcleverness: होशियारीinvestigation: जांचevidence: सबूतstorage: भंडारणembarrassment: शर्मिंदगीintentions: इरादेresponsibility: जिम्मेदारीunderstanding: समझदारीtrust: विश्वासconclusion: वाकया समाप्तtolerant: सहनशीलcolleagues: सहयोगियोंwisdom: समझदारीmaturity: परिपक्वताsecret: गुप्तnodded: सहमति में सिर हिलायाapologetic: माफ़ी मांगने वालाappreciated: सराहा

Stephen Grootes speaks to Ruaan Louw, Managing Director of iDexis, about the company's decision to appeal a recent High Court judgment and regulatory findings relating to its compounding of GLP-1 and GIP medicines. iDexis maintains that its products were safe, says independent testing found no evidence of sterility failures, and argues that regulators were aware of its compounding activities long before the dispute reached court. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the landscape of these dynamic sectors. Starting with Ipsen's Dysport, which has made notable strides in its Phase 3 trials for migraine prevention. The trials covered both episodic and chronic conditions, marking a first in the neurotoxin market. Dysport's success positions it as a formidable competitor to AbbVie's Botox, expanding therapeutic options for individuals battling migraine disorders. This achievement showcases the potential efficacy of botulinum toxin-based therapies in neurology and pain management, offering promising new avenues for patient care. In regulatory news, Boehringer Ingelheim has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for Jascayd, a small molecule PDE4B inhibitor with antifibrotic properties. This approval marks a significant milestone in the treatment of idiopathic and progressive pulmonary fibrosis. Jascayd's addition to the therapeutic arsenal offers new hope for managing this debilitating condition, emphasizing the ongoing efforts to improve patient outcomes through innovative treatments. The arena of business development sees HanChorBio partnering with InxMed to advance oncology research. By combining HCB101 with FAK inhibitors and FAP-targeted ADCs, this collaboration aims to leverage antibody and small molecule drug discovery techniques. The goal is to develop innovative cancer treatments that could redefine therapeutic approaches in oncology. Keenova Therapeutics has also reported success with Xiaflex for plantar fibromatosis. This enzyme injection therapy offers a novel approach by targeting collagen, thus providing an innovative solution for musculoskeletal conditions. Similarly, Fate Therapeutics' FT819, an off-the-shelf CAR-T therapy, has shown early promise in tackling treatment-resistant systemic sclerosis, underscoring the potential of cell therapies beyond oncology. Meanwhile, MindRank's successful Series B funding round of $52 million highlights the growing role of AI platforms in drug discovery. The funding will propel its AI-discovered oral GLP-1 obesity pill into Phase III trials, exemplifying how technology-driven solutions are gaining traction in addressing metabolic diseases like obesity. On the regulatory front, Saol Therapeutics has resubmitted SL1009 (DCA) to the FDA for pyruvate dehydrogenase complex deficiency. This submission underscores ongoing efforts to address rare metabolic disorders using small molecule therapies. Additionally, Sanofi's concessions to the EU regarding flu vaccine marketing illustrate the complexities of competitive dynamics and regulatory scrutiny within the vaccine market. However, not all developments are favorable. AstraZeneca and Ionis Pharmaceuticals faced a setback as their drug Wainua failed its Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy. This outcome highlights the challenges inherent in developing effective treatments for complex cardiovascular conditions. Meanwhile, regulatory processes remain contentious as the FDA pauses its release of complete response letters amid debates over proprietary information disclosures. In another noteworthy development, GSK has terminated its $2.2 billion collaboration with Alector after underwhelming results from Alzheimer's drug trials. This decision highlights both financial implications and strategic shifts as companies reassess risk tolerance in neurodegenerative disease research. Conversely, Roche's success with its KRAS G12C inhibitor divarasib in Phase 3 lung cancer trials underscores the promise of precision medicine. Divarasib outperformed competitors Amgen's Lumakras and Bristol Myers Squibb's Krazati, positioning Roche to potentially redefine standards of care based on genetic profiles. In a move reflecting industry trends towards collaboration and innovation risk-sharing models, AstraZeneca has partnered with Sino Biopharmaceutical on respiratory disease research. This strategic alliance represents a substantial investment aimed at expanding AstraZeneca's pipeline in respiratory therapeutics. Lastly, amidst these developments, psychedelic drugs are experiencing a renaissance in psychiatric care. Companies like Compass Pathways are pioneering clinical validation for their use in treating depression, signaling a potential paradigm shift from traditional SSRIs to newer therapeutic classes pending safety and efficacy data. Overall, these stories illustrate a dynamic interplay of scientific progress and regulatory navigation within the pharmaceutical and biotech sectors. While challenges persist—particularly in neurodegenerative disease treatment—the breakthroughs in oncology and metabolic disorder therapeutics offer hopeful prospects for improving patient care. As these industries continue evolving, integrating advanced technologies such as AI will likely play a pivotal role in shaping future therapeutic landscapes.Support the show

India is often called the ‘pharmacy of the world' — it exports one-fifth of the world's generic medicines and meets over half of the global vaccines demand. Yet when it comes to discovering the next breakthrough medicine, India's contribution remains surprisingly small.----more----Read full article here: https://theprint.in/feature/india-manufacturing-medicines-discovering-funding-key/2973560/

Clinical trial support companies are rapidly adopting AI, but sponsors have been more hesitant. Raj Indupuri, CEO of eClinical Solutions, gives the top three reasons behind the holdup in AI agent deployment. He explains the specific pattern of uptake for these agents, the required human-in-the-loop oversight, and how the agents can improve clinical trial velocity. Host Deborah Borfitz also gives the latest news on a highly acclaimed treatment for pancreatic cancer, filling evidence gaps in drug safety during pregnancy, guidelines for routinely collected health data for research purposes, an innovative portal aiding bidirectional communication with patients, and more. Show Notes News Roundup KRAS inhibitor therapy for pancreatic cancer Study in The New England Journal of Medicine  News on the Fred Hutch Cancer Center website  Target trial emulation in rural areas Perspective in the Medical Journal of Australia News on the Griffith University website   AI for improving drug safety during pregnancy Report from the Journal of Medical Internet Research Guidelines on the use of routinely collected data Article in The BMJ New regulatory framework in the U.K. Press release by the Medicines and Healthcare products Regulatory Agency  Participant Engagement Portal Article in JNCI Cancer Spectrum Press release from the Alliance for Clinical Trials in Oncology The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

Americans pay roughly three times as much for prescription meds as people in other wealthy nations. But why? Tahir Amin argues it's largely to do with how our patent systems work. He's been on both sides of the issue: He spent a decade as an intellectual property lawyer, helping corporations use patents to protect their bottom lines. Then he moved to India and saw firsthand how the global patent system hampered access to HIV drugs. That led him to shift gears and create an advocacy organization aimed at changing the patent system to make access to medicines more equitable. He chats with Flora about how it all works, and his new book, “Pharma Monopoly.” Read an excerpt from “Pharma Monopoly: The Battle for the Future of Medicines.” Guest: Tahir Amin is a co-author of “Pharma Monopoly: The Battle for the Future of Medicines” and a founder and CEO of Initiatives for Medicine Access and Knowledge (I-MAK).  Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

For the last episode in the second series of Magic and Medicines, we're talking about Palmistry and Phrenology!We start by looking at uses of palmistry across the world, from Vedic astrology with Hindu Jyotish over to the divination practices of the Chinese Ming dynasty.We discuss whether or not it's true that Aristotle discovered an ancient palmistry text and got Alexander the Great into the art, and explore the stereotypes associated with fortune telling in general, and some nasty xenophobic history.Then, we have a look at our own hands, and try and work out whether we've got 'fire hands' or 'air hands', and what the lines in our palms say about us.In the third part of the episode, we look at the concept of phrenology, from its roots as possible brain science through to its manipulation and abuse by proponents of eugenics, and its alarming similarity to the work done by some algorithms today...We really hope you enjoy the episode, and we will speak to you again on Thursday with a new tale from the Red Fairy Book, Minnikin!Three Ravens is an English Myth and Folklore podcast hosted by award-winning writers Martin Vaux and Eleanor Conlon.Released on Mondays, each weekly episode focuses on one of England's 39 historic counties, exploring the history, folklore and traditions of the area, from ghosts and mermaids to mythical monsters, half-forgotten heroes, bloody legends, and much, much more. Then, and most importantly, the pair take turns to tell a new version of an ancient story from that county - all before discussing what that tale might mean, where it might have come from, and the truths it reveals about England's hidden past...Bonus Episodes are released on Thursdays plus Local Legends episodes on Saturdays - interviews with acclaimed authors, folklorists, podcasters and historians with unique perspectives on that week's county.With a range of exclusive content on Patreon, too, including audio ghost tours, the Three Ravens Newsletter, and monthly Three Ravens Film Club episodes about folk horror films from across the decades, why not join us around the campfire and listen in?REGISTER FOR THE TALES OF SOUTHERN ENGLAND TOURVisit our website Join our Patreon Social media channels and sponsors Hosted on Acast. See acast.com/privacy for more information.

REPLAY: "For the Love of" Our Sacred Medicines Join us in re-listening to this special episode with Robin Wall Kimmerer, award winning author, citizen of the Potawatomi Nation, mother, scholar, scientist, and a giver of knowledge. Auntie Lisa opens this special episode with a new introduction, reflecting on our time spent with Robin! Originally part of our "For the Love of" series in February, this episode is centered on our sacred medicines as the Aunties dive deep into conversation with Robin, highlighting the love and abundance mother earth provides. Please sit back, enjoy and take in the lessons that Robin is so talented in sharing with us!  Wabanaki Words Used: Apc-oc (again in the future, parting, good-bye, farewell) - https://pmportal.org/dictionary/apc-oc   Topics Discussed:   Robin Wall Kimmerer - https://www.robinwallkimmerer.com/ “Braiding Sweetgrass” by Robin Wall Kimmerer - https://bookshop.org/p/books/braiding-sweetgrass-indigenous-wisdom-scientific-knowledge-and-the-teachings-of-plants-robin-wall-kimmerer/6fa4d296293d20e8?ean=9781571313560&next=t Carlisle Indian School - https://www.npca.org/parks/carlisle-federal-indian-boarding-school-national-monument “The Serviceberry” by Robin Wall Kimmerer - https://bookshop.org/p/books/the-serviceberry-abundance-and-reciprocity-in-the-natural-world-robin-wall-kimmerer/11103aae5b752d02?aid=86677&ean=9781668072240&listref=robin-wall-kimmerer&next=t “The First Blade of Sweetgrass” by Suzanne Greenlaw and Gabriel Frey - https://www.amazon.com/First-Blade-Sweetgrass-Suzanne-Greenlaw/dp/0884487601 Monique Smith - https://wordfest.com/artist/monique-gray-smith/ “Bud Finds Her Gift” by Robin Wall Kimmerer - https://bookshop.org/p/books/bud-finds-her-gift-robin-wall-kimmerer/615a02894e9290a1?aid=86677&ean=9780063324428&listref=robin-wall-kimmerer&next=t The Briar Patch - https://briarpatchbooks.square.site/ Plant Baby Plant - https://plantbabyplant.com/   Wabanaki Tribal Nations: Houlton Band of Maliseet Houlton Band of Maliseet Indians | Littleton, ME (maliseets.net) Mi'kmaq Mi'kmaq Nation | Presque Isle, ME (micmac-nsn.gov) Passamaquoddy Tribe Indian Township Passamaquoddy Tribe @ Indian Township | Peskotomuhkati Motahkomikuk Passamaquoddy Tribe Sipayik Sipayik Tribal Government – Sipayik (wabanaki.com) Penobscot Nation Penobscot Nation | Departments & Info | Indian Island, Maine   Special Thanks/Woliwon:  Guest: Robin Wall Kimmerer Producer: Gavin Allen Podcast Team: Macy Flanders

Episode Summary Tahir Amin started out wanting to play professional football in England. He found law instead, and specifically intellectual property law in the early 1990s, when the field was still new enough to feel cutting edge. After a decade of commercial IP practice in the UK and the US, he moved to India in 2004 to understand what the new global IP rules were doing to the people they never accounted for. He arrived just as India was being required to comply with WTO patent rules that would affect access to HIV medicines costing tens of thousands of dollars a year. That experience led him to co-found I-MAK in 2006. In this conversation, Amin walks Rubino through the political economy of drug patents: how neoliberal policy from the late 1970s onward handed control of publicly funded research to private companies, how those companies built out sprawling patent portfolios to delay generic competition, and how the word "innovation" became a shield against any real scrutiny. He also talks about what I-MAK's work has achieved, the blowback it has faced, and why he considers himself a "cynical optimist" who believes the long game is the only game worth playing. Key Takeaways Patent stacking is the norm, not the exception. Novo Nordisk filed more than 320 patent applications around the single active ingredient in the Ozempic family of drugs. 1 in 3 Americans are skipping doses or cutting pills to afford their medications. This is a policy problem rooted in decisions made over the past four decades. The word "innovation" replaced "invention" deliberately around 1976–77, allowing corporations to privatize public-funded knowledge and charge rent for it. I-MAK's public patent database puts the evidence on the table. The pharma industry attacks the messenger rather than engaging the data. Incrementalism is the system's release valve. Real change requires playing the long game, not chasing the next quick win. Links & Resources Above the Law The Jabot Podcast Tahir Amin at I-MAK Pharma Monopoly: The Battle for the Future of Medicines by Tahir Amin (book) Keywords pharmaceutical patents, drug pricing, patent monopoly, medicine access, IP law, I-MAK, Tahir Amin, patent stacking, Ozempic patents, Novo Nordisk, innovation myth, neoliberalism, affordable medicine, generic drugs, biosimilars, patent reform, WTO patent law, drug affordability, pharma policy, Jabot podcast Episode Highlights 00:08:18 - 00:09:16 Amin explains the founding of I-MAC and the need to challenge systems treating public knowledge as monopoly property. 00:12:49 - 00:13:33 The survey data: 1 in 3 Americans are skipping or rationing medications, a Western problem as much as a global one. 00:16:12 - 00:16:55 Novo Nordisk's 320+ patent applications on the Ozempic active ingredient, and how that data changed the Congressional conversation. 00:21:52 - 00:24:54 The linguistic shift from "invention" to "innovation" after the late 1970s, and why the distinction matters for policy. 00:30:27 - 00:31:32 Why incrementalism is the system's release valve, and the case for committing to real, structural change over the long run.  

In this final episode of Series 8, we are joined by Dr Ellie Cannon — NHS and private GP, women's health specialist, Mail on Sunday health columnist, and author of The Little Book of HRT. The conversation ranges from the evolving landscape of menopause treatment and the dangers of health misinformation online to the role of the media in shaping public health behaviour.Ellie reflects on her 18-year career as a GP on Abbey Road in North London and her work bringing calm, evidence-based medicine to an increasingly crowded and often sensationalist health media landscape. We explore the nuances of HRT prescribing, including the thorny topic of duration of use, while also discussing her earlier book Is Your Job Making You Ill? and the profound impact that work and workplace relationships can have on health and wellbeing.The episode's micro discussion examines a systematic review of patient access to clinical notes, weighing the benefits for patient empowerment and safety against concerns about data quality, clinician intentions and unintended consequences.Impact of online patient access to clinical notes on quality of care: a systematic review https://qualitysafety.bmj.com/content/35/4/266As with all of our guests, Ellie shares with us her Memory Evoking Medicine, a career anthem and book. Her book choice is particularly poignant.The Little Book of HRT: https://www.bloomsbury.com/uk/little-book-of-hrt-9781399423694/Is Your Job Making You Ill? https://www.hachette.co.uk/titles/dr-ellie-cannon/is-your-job-making-you-ill/9780349416755/From Prescription to Ocean — A TEDx Talk by Jamie HayesWe're incredibly proud to share that Aural Apothecary co-host Jamie Hayes has taken to the TEDx stage with a thought-provoking talk:  Prescription to Ocean: The Hidden Impact of Medicines https://www.youtube.com/watch?v=swCLNaAG5qYJamie explores a fascinating and urgent question: What happens to our medicines once they leave the prescription pad — and how do they impact the world beyond the patient? It's a journey that connects healthcare, the environment, and our shared responsibility for the future. You'll never think about prescribing (or taking) medicines in quite the same way again.Please take a few minutes to watch, reflect, and share — this is a conversation worth having.Please follow us onLinkedIn! Let us know what you think of the show. https://www.linkedin.com/company/auralapothecary/You can listen to the Aural Apothecary playlist here; https://open.spotify.com/playlist/3OsWj4w8sxsvuwR9zMXgn5?si=tiHXrQI7QsGtSQwPyz1KBg You can view the Aural Apothecary Library here;  https://litalist.com/shelf/view-bookcase?publicId=KN6E3OOur website is https://www.theauralapothecary.com/To get in touch follow us on LinkedIn, Bluesky and X @auralapothecary or email us at auralapothecarypod@gmail.com. Don't forget to rate us and comment wherever you have got this podcast from.

New Zealanders are waiting almost twice as other countries to get modern medicines. US pharmaceutical research shows New Zealand's processes for registering, approving and funding modern medicines are the slowest out of 20 OECD countries. Medicine NZ chief executive Graeme Jarvis says other countries have similar wealth ratings and size - so we can't blame being poor and small. "You want to give patients the access now, because if they wait too long, they become the ambulance at the bottom of the cliff and the rest of the health system, which is over-worked as it is, is having to deal with the patients in the interim." LISTEN ABOVESee omnystudio.com/listener for privacy information.

4th Step – On Obedience The Ladder of Divine Ascent was written primarily for monks. However, the words of Saint John Climacus at the beginning of the first chapter indicate that his intention is to address every person who longs for salvation. He says: “The gates of eternal life are open to all. The goal of our life is to follow Christ and to become like Him in His divine love.”

Kelly sits down with Dr. Jeremy Levin, Executive Chairman and founder of Ovid Therapeutics, a public company focused on medicines for epilepsies and seizure-related brain disorders. He has a fantastic new book titled “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust.”  “Misinformation spreads faster than corrections.”  “Talented people learn that candor carries risk.”  “Medicines […]

Professor Michael Barry, Director of the NCPE.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape. Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for hereditary angioedema. This gene therapy utilizes CRISPR technology combined with antisense oligonucleotides, highlighting the transformative potential of genetic editing techniques. The success of this approach underscores CRISPR's promise in offering long-term solutions through single-dose treatments, setting a benchmark for future therapies targeting genetic disorders. Regulatory dynamics are also shifting, as evidenced by Germany's move to abandon its variable drug discount plans after major pharmaceutical companies like Boehringer Ingelheim and Eli Lilly withdrew investments. This decision highlights the ongoing complexities and challenges in drug pricing policies, which are vital for maintaining equitable access to medications while ensuring economic sustainability for pharmaceutical companies. On the manufacturing front, Recipharm is investing significantly to upgrade its U.S. production capabilities in response to rising demand for biologics. This trend reflects an industry-wide push towards expanding biologic drug manufacturing infrastructure, driven by biologics' potential for personalized medicine applications. Similarly, Eisai has secured a UK government grant to expand its Hatfield plant for monoclonal antibody production, while Johnson & Johnson is investing $1 billion to enhance Acuvue contact lens production. These expansions illustrate how major companies are bolstering manufacturing capabilities to support strategic growth and meet increasing product demand. Merck & Co.'s partnership with Protillion Biosciences, valued at $510 million, exemplifies the growing integration of AI/ML technology in drug discovery. This collaboration aims to leverage Protillion's Prot-map protein design platform to enhance data generation and accelerate biologics development, illustrating how artificial intelligence is streamlining drug discovery processes. In clinical trials, promising developments continue to emerge. Spyre Therapeutics reported that SPY002 met its Phase 2 primary endpoint in ulcerative colitis with anti-TL1A results, positioning it as a potential leader in autoimmune disease therapies. Edgewise Therapeutics also presented supportive Phase 2 data for EDG-7500, which targets hypertrophic cardiomyopathy, paving the way for Phase 3 trials. These advancements highlight the potential of small molecules and combination therapies in addressing complex diseases. Additionally, Alto Neuroscience's ALTO-207 has shown benefits for anhedonia in major depressive disorder patients through independent Phase 2 data. This underscores ongoing progress in treating neurological disorders using innovative combinations of established compounds like dopamine agonists and ondansetron. The landscape is further enriched by Moderna's expansion plans. Anticipating up to three new product launches between 2027 and 2028, Moderna is restructuring its operations under new leadership. This strategic realignment aims to streamline processes across commercial, manufacturing, and R&D divisions ahead of significant product launches. Regulatory collaboration is advancing, with the FDA and UK's Medicines and Healthcare products Regulatory Agency (MHRA) initiating a new liaison program. This initiative aims to harmonize regulatory responses across borders, potentially accelerating drug approvals.Support the show

The Government is considering expanding prescribing powers for emergency paramedics, allowing them to prescribe certain medicines, including antibiotics, for conditions such as respiratory and ear infections.  Supporters say the move could improve access to healthcare, particularly in underserved communities, but some experts are warning that stronger safeguards are needed to prevent unnecessary antibiotic use and growing antimicrobial resistance.  Producer Pranuja spoke with Professor Bruce Arroll from the University of Auckland about the safeguards needed with this policy to protect public health.

Scientists have made a new scientific breakthrough in the study of the human body.Researchers in the United States have discovered something amazing: a third circulatory system within the human body.Alongside the previously known cardiovascular and lymphatic systems, this interstitium system (as it's being called) appears to allow the different organs of the human body to pass things along to one another.Which in-and-of-itself is an amazing discovery, but it's made even more exciting by the fact that this newly discovered system maps very well onto the model of the human body that's been used in traditional Eastern medicine for thousands of years (in practices like acupuncture, for instance).Meaning, this discovery might very well be the missing link between Western and Eastern medicine.Let's go through the details together.

In this episode, I'm joined by global health advocate, founder and CEO of the Initiative for Medicines, Access, and Knowledge (I-MAK), and author Tahir Amin to discuss his groundbreaking book Pharma Monopoly: The Battle for the Future of Medicines. Drawing on decades of work challenging pharmaceutical patents and advocating for equitable access to medicine, Amin argues that the modern drug system is shaped not only by science, but by law, politics, economics, and monopoly power. From insulin and cancer drugs to the lessons of the COVID-19 pandemic, this conversation explores who controls medicine, who profits from it, and what a more just global health system could look like.

We're growling, purring and hissing our way into this month's Magic and Medicines episode to talk all about Familiars and Animal Magic!We start by talking about animistic beliefs in early societies, along with associations of animals with particular deities, before diving into Medieval and Renaissance ideas about witches' familiars documented in witch trial materials.With Vinegar Tom, Sacke-and-Sugar and Pecke-in-the-Crowne frolicking about our feet, we explore beliefs about how familiars might be summoned - and whether or not they are really something far more sinister than a magical companion. There's a bit of Jungian psychology, of course, and an eclectic selection of beliefs from around the world - but are appearances of animals within spiritual practices really just symbols to assist us with self-development?Moving into the 21st century, we discuss neo-shamanism, power animals, and how domestic pets can be spiritually comforting to practitioners of magic and spirituality today, before rounding out the conversation by looking to the future with digital familiars and AI companions!We really hope you enjoy the episode, and we will speak to you again on Thursday with The Golden Branch, a longer Lang tale!Three Ravens is an English Myth and Folklore podcast hosted by award-winning writers Martin Vaux and Eleanor Conlon.Released on Mondays, each weekly episode focuses on one of England's 39 historic counties, exploring the history, folklore and traditions of the area, from ghosts and mermaids to mythical monsters, half-forgotten heroes, bloody legends, and much, much more. Then, and most importantly, the pair take turns to tell a new version of an ancient story from that county - all before discussing what that tale might mean, where it might have come from, and the truths it reveals about England's hidden past...Bonus Episodes are released on Thursdays plus Local Legends episodes on Saturdays - interviews with acclaimed authors, folklorists, podcasters and historians with unique perspectives on that week's county.With a range of exclusive content on Patreon, too, including audio ghost tours, the Three Ravens Newsletter, and monthly Three Ravens Film Club episodes about folk horror films from across the decades, why not join us around the campfire and listen in?REGISTER FOR THE TALES OF SOUTHERN ENGLAND TOURVisit our website Join our Patreon Social media channels and sponsors Hosted on Acast. See acast.com/privacy for more information.

John Maytham is joined by Dr Lindiwe Gumede, Senior Lecturer and Head of the Department of Medical Imaging and Radiation Sciences at the University of Johannesburg, whose research explores why these conversations are not happening and how bridging the gap between traditional and Western medicine could ultimately save lives. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Paramedics will be authorised to prescribe medicines in a move aimed at reducing pressure on emergency departments. Hato Hone St John deputy chief executive of clinical services, Jon Moores spoke to Ingrid Hipkiss.

Welcome to a warm summer's evening in a Medieval barn, complete with twilight birdsong, for Three Ravens Live @ Chiltern Open Air Museum!Set across 45 acres of the Chiltern Hills, "COAM" rescues endangered historic buildings and reconstructs them at its picturesque site - one where a working historic farm and traditional craftspeople continue Buckinghamshire's old folk occupations and ensure they live on in the modern day. Learn more here.This recording, made last Saturday evening, is a celebration of not just COAM and the Chiltern Hills but the entire county of 'Bucks' - a place once ruled over by the pagan king Cymbeline, through which Woden dug a very big ditch, and where Little Witches might hypnotize your sheep before hippy-hopping away over the nearest hedgerow...From the county's ancient gold and silver mints at Aylesbury to the furniture makers of High Wycombe - at least two of whom stuck around after death - local delicacies including the Buckinghamshire Bacon Badger to Augustinian monks catching devils in their shoes, Bucks might not have a particular reputation for being folky, but that's only because the county's people have been keeping quiet about it! Including performances of traditional folk songs Green Bushes and The Barley Mow by Ben and Eleanor, and Eleanor's haunting live performance of local folktale A Promise Kept with dramatic live underscoring, it's an evening to remember, interrupted by a pigeon and topped off with a Q&A session with our lovely live audience!We really hope you enjoy it, and will speak to you again on Monday for the penultimate episode of our Bonus Series Magic and Medicines, all about Familiars and Animal Magic!P.S. We recorded a whole second episode after the audience went home, during which we explored the museum's historic buildings and searched for ghosts between midnight and 2am. We still have work to do to edit it all together, but that decidedly spooky recording will be coming out on the Three Ravens Patreon during July!Three Ravens is an English myth and folklore podcast hosted by Eleanor Conlon and Martin Vaux.Released on Mondays, each weekly episode focuses on one of England or Wales' 39 historic counties, exploring the history, folklore and traditions of the area, from ghosts and mermaids to mythical monsters, half-forgotten heroes, bloody legends, and much, much more. Then, and most importantly, the pair take turns to tell a new version of a traditional story from that county - all before discussing what that tale might mean, where it might have come from, and the truths it reveals about England's hidden past...Bonus Episodes are released on Thursdays plus Local Legends episodes - interviews with acclaimed authors, folklorists, podcasters and historians with unique perspectives on that week's county - and Live Shows come out on Saturdays.With a range of exclusive content on Patreon too, including audio ghost tours, the Three Ravens Newsletter, and monthly Three Ravens Film Club episodes about folk horror films from across the decades, why not join us around the campfire and listen in?REGISTER FOR THE TALES OF SOUTHERN ENGLAND TOURVisit our website Join our Patreon Social media channels and sponsors Hosted on Acast. See acast.com/privacy for more information.

Paramedics may have to undertake further training, so they can prescribe medicines. Planned changes to the Medicines Act are set to allow paramedics to be prescribers, with consultation underway on what medicines can be authorised. The Government says training programmes will be established for them to gain the necessary qualifications. Health Minister Simeon Brown says it's important New Zealand maximises its paramedic workforce to benefit communities. "Our paramedic workforce is probably best known for the work they do on ambulances, but paramedics also work in primary care and urgent care, and in a range of other areas in the community as well. So by expanding their scope of practice and allowing them to prescribe - it takes pressure off other parts of the workforce. LISTEN ABOVESee omnystudio.com/listener for privacy information.

The CEO of Kalshi joins to discuss the company's latest product announcements and the regulatory environment for prediction markets. Then, Former Defense Secretary Mark Esper helps break down the latest headlines on the war with Iran. We also speak with the CEO of D-Wave Quantum following the U.S. government's recent investment in quantum companies. Plus, the CEO of Revolution Medicines joins to discuss the company's pancreatic cancer drug that nearly doubled survival rates.   Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A new book examines the how pharmaceutical corporations set high drug prices and what can be done about it.

In this episode, Janet Borges presents Laura Stropes' clinical guide to supporting female fertility with prepared Chinese medicines. Exploring the four phases of the menstrual cycle through a TCM lens, Janet discusses treatment principles, hormonal and energetic shifts, and commonly used formulas to support menstruation, ovulation, implantation, and reproductive health.She also examines how prepared formulas and modular herbal strategies can be used to tailor care, improve patient compliance, and support fertility treatment through each stage of the cycle.You can access the article here: https://www.mayway.com/blogs/articles/optimizing-female-fertility-with-prepared-chinese-medicinesDownload your free poster here: https://www.mayway.com/products/four-phase-tcm-fertility-posterSee our Monthly Practitioner Discounts https://www.mayway.com/monthly-specialsSign up for the Mayway Newsletterhttps://www.mayway.com/newsletter-signupFollow ushttps://www.facebook.com/MaywayHerbs/https://www.instagram.com/maywayherbs/

Ask Flora Funga Podcast anything OR Leave a ReviewThis episode was such a fun, open-minded wander through fungi, philosophy, psychedelics, podcasting, and the weird little threads that connect us all. KK sat down with Joel and Jacob from The Open Minded Podcast to talk about their journey as curious young hosts exploring psychology, religion, consciousness, and the big questions of life. The conversation drifted into mushrooms, plant medicine, psychedelic experiences, ego, perception, and how these moments can change the way we see ourselves and the world around us. They also dug into what mushroom culture looks like in the UK compared to the U.S., touching on stigma, underground communities, and how normalized alcohol is while fungi still gets side-eyed. It was a thoughtful, funny, and curiosity-filled chat about growth, awareness, and staying open to the mystery. Open Minded PodcastToday's episode is supported by Schedule 35. As always, please do your own research, know your local laws, and make informed choices that are right for you. This is adult-oriented content, and nothing we share here is medical advice or a recommendation to use any substance. Schedule 35 is part of the larger conversation happening around mushrooms, plant medicine, and changing cultural perspectives. For listeners in places where their products are legal and appropriate, you can learn more through Schedule 35 and use code FLORAFUNGA for 15% off.Thank you for supporting the sponsors that help keep Flora Funga growing.I got a new phone number to text in with any questions, comments, or photos!727-477-5974 Support the showText (727) 477-5974 Flora Funga Phone with your questions, comments, concerns, and IDs Flora Funga: Calm & Collected Tincture — Flora Funga PodcastGoFundMEIf you like the podcast please think of donating to Keep the show happening  $keenie19 on Cash AppFollow my other social media sites to interact and engage with me:Email me to be on the podcast or inperson Interview: floraandfungapodcast@gmail.comFacebookInstagramTwitterTikTokYouTubePatreon---------------------------------------------------------------------------Zbiotics: "FLORA10"Drink ZBiotics before drinking alcohol-Alcohol produces acetaldehyde, a byproduct that your next day...

While many St. Louisans are celebrating signs of the start of summer, heat-related illnesses can put a damper on summertime fun — and can lead to serious harm. In this encore episode, clinical assistant professor and community pharmacist Catherine Gilmore joins St. Louis on the Air to discuss the science behind what happens to the body when it fails to regulate heat and how certain types of medication can increase the risk of heat intolerance.

Association for Accessible Medicines v. Bonta

Millions of seniors struggle with muscle and joint pain daily. Discover proven natural methods, from lifestyle changes to topical relief, that reduce pain without medication. Hear real success stories and science-backed solutions that restore mobility and independence. Learn more at https://GetRapidPainRelief.com Nutriomo Labs Pte Ltd (N-Labs) City: Camas Address: 2025 NE 3rd Avenue #2025 Website: http://getarcticblast.com

Stephen Grootes speaks to Corné van Walbeek, Professor at UCT's School of Economics and the Director of REEP, about South Africa’s plan to introduce track-and-trace technology that will allow consumers to scan alcohol, medicines, and cigarettes to verify their authenticity and crack down on counterfeit goods. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Dr. Spencer Nadolsky and Karl sit down with Dr. Susan Brian, a Yale-trained endocrinologist, certified menopause provider, and medical director of a clinic with seven endocrinologists who runs an active bone fragility fracture clinic, to answer the question that has been flooding social media since a viral abstract with two fake bones on a surgical table convinced people their skeletons are quietly dissolving.Follow Dr. Susan here In this episode they cover why the preclinical and mechanistic data on GLP-1 medicines actually points toward bone benefit rather than harm by improving osteoblast activity and reducing osteoclast activity, why the meta-analyses from over two decades of GLP-1 use in type 2 diabetes show reduced fracture risk rather than increased risk, what the recent Israeli retrospective cohort study actually found and why an 11% increased fragility fracture signal in older adults on GLP-1 for diabetes versus other treatments deserves attention without panic, why almost every nutritional deficiency flagged in GLP-1 patients turns out to be vitamin D deficiency that likely predated the medicine, why the degree of weight loss matters far more than the medicine itself and how the one to two pounds per week threshold and the one percent of body weight per week guideline translate into real clinical practice, what the Hansen JAMA 2024 study showed about GLP-1 alone versus GLP-1 with resistance training and why that finding is the single most important takeaway for anyone on these medicines, why Spencer has idiopathic hypercalciuria and was spilling 650 milligrams of calcium per day in his urine before anyone caught it, how romosozumab works and why it is the most powerful bone building medicine available, why Dr. Brian orders baseline bone densities on patients well before the standard screening age and why insurance almost always covers it, and why comparing GLP-1 nutritional risk to bariatric surgery nutritional risk is not even close to an apples to apples comparison. The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Associate Health Minister David Seymour welcomes Pharmac's proposal to change funding criteria for more type 2 diabetes medicines based on clinical need. Under the proposal, 25,000 more diabetic Kiwis will gain access to the treatments over the next few years. David Seymour says there's a lot of potential in investing in more GLP-1 medications to prevent other health problems impacting people down the line. "We've made a lot of progress on this kind of whole of society approach to funding medicines that will save us money in the long term, but that's some of the challenges we've run into so far." Pharmac has since confirmed the ethnicity criteria reference refers to the diabetes medicine consultation and they have separate recommendations for semaglutide funding applications. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Good morning. A German holiday maker has successfully sued his tour operator alleging that he had spent 20 minutes every morning trying, without success, to find sun loungers by the pool. He was on the case at 6 a.m. but the loungers were already covered in towels, though they often remained unoccupied through the day whilst he and his family lay on the ground. The Court awarded him damages. Another tourist commenting on this story gleefully recalls an alternative solution to the problem: 'it soon stopped when some lads were going down in the middle of the night and throwing all the towels into the pool.' But our more law abiding litigant hopes that the fear of legal action will spur tour operators and hotels to devise fair and rational allocation systems for these highly contested spaces. As far as I know, Thomas Hobbes never took a package holiday, but having lived through the turmoil of the English civil war and its aftermath, he would not have been surprised by stories of so called 'sunbed wars': 'during the time men live without a common power to keep them all in awe' so he tells us in his great work Leviathan, 'they are in that condition called war'. Hobbes' father was a vicar, and his relationship to Christianity is complicated, as is perhaps not uncommon in such circumstances. But Hobbes' views are not so different from Augustine's, who was in the habit of noting that just as divine history begins with the story of Cain killing Abel, so world history begins with the story of Romulus killing Remus. For Augustine, it is 'every man against every man' as Hobbes puts it, and not just poolside. I know nothing about the personal beliefs of our German litigant, but I think he is a bit of a hero for spurning two obvious but unhelpful responses to this gloomy diagnosis of the human condition. One is to take the law into your own hands - throwing the towels in the pool - which could end rather badly of course. The other is just to grumble - and who doesn't enjoy a good grumble? Of all the things in the world which are unfairly and irrationally distributed, sun loungers are by no means the most significant. Houses lie empty, while children sleep on the streets. Food goes to waste while there is hunger. Medicines expire on shelves, and diseases go untreated. Christians have never needed to be told that humans can be deeply selfish, but everywhere the faith is truly alive there have been dreamers and prophets, from St Francis to Martin Luther King, who have contended that the world doesn't have to be determined by our flawed natures, even if we need to reckon with their existence and character. Who knows whether the sunbed wars will come to an end, but Mr Eggert - let's give him his name and due credit – by pushing the tour operators and hotels into action has given us hope for bloodless revolutions.

This new episode of Magic and Medicines has perhaps been a long time coming - we're finally talking all about Wicca!We trace earlier ideas which informed the path scholars call a 'magico-religion' back to the early 19th century, when historians first hypothesised about the existing of an ancient, secret witch cult.Through texts like Charles Leland's Aradia, via Frazer's The Golden Bough, to the highly influential (if historically dubious) work of Margaret Murray, we arrive in the melting pot of secret societies and orders which emerged from Western esotericism in the first part of the 20th century.Although such theories left most members of the Folklore Society cold, they thoroughly inspired Gerald Gardner, and the development of what would become Wicca began.It's a twisty, turny journey, with witch traditions of dubious ancient origin, Cones of Power, and many, many breakaway branches, all the way through to sparkling Geocities sites, teen witches, and the rich, eclectic patchwork that is international Wicca today. We really hope you enjoy the episode, and we will speak to you again on Thursday with another double bill of Lang Tales!Three Ravens is an English Myth and Folklore podcast hosted by award-winning writers Martin Vaux and Eleanor Conlon.Released on Mondays, each weekly episode focuses on one of England's 39 historic counties, exploring the history, folklore and traditions of the area, from ghosts and mermaids to mythical monsters, half-forgotten heroes, bloody legends, and much, much more. Then, and most importantly, the pair take turns to tell a new version of an ancient story from that county - all before discussing what that tale might mean, where it might have come from, and the truths it reveals about England's hidden past...Bonus Episodes are released on Thursdays plus Local Legends episodes on Saturdays - interviews with acclaimed authors, folklorists, podcasters and historians with unique perspectives on that week's county.With a range of exclusive content on Patreon, too, including audio ghost tours, the Three Ravens Newsletter, and monthly Three Ravens Film Club episodes about folk horror films from across the decades, why not join us around the campfire and listen in?REGISTER FOR THE TALES OF SOUTHERN ENGLAND TOURVisit our website Join our Patreon Social media channels and sponsors Hosted on Acast. See acast.com/privacy for more information.

Are we a house/show divided against itself on this topic? The results are too, as we welcome Harmeet Dhillon on the show, Asst. AG of the USA, and Jim Talent tells us if/when the Strait of Hormuz will determine when see your gas prices return to normal.

Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.

Gleb Zilberstein is my guest in this episode of the Physics World Weekly podcast. A physicist by training, Zilberstein applies the principles of proteomics to the study of historical objects including Renaissance manuscripts. He is also a director of Israel-based SpringStyle Tech Design, which has created a special film that lifts proteins from the surfaces of historical objects. Analysis of these proteins provides  important information about how those objects were used. In a recent paper, Zilberstein and colleagues studied protein residues on a well-thumbed book of medical recipes that was published in Germany in 1531. He explains how their analysis provides a new view into how medical practitioners used the book and what sorts of concoctions they were making. Astonishingly, the team found evidence that European readers had access to ingredients derived from hippopotamuses. Some papers about the application of proteomics to historical research: The Scientific Analysis of Renaissance Recipes Count Dracula Resurrected  EVA Technology and Proteomics: A Two-Pronged Attack on Cultural Heritage

People may soon be able to bypass the GP and head to the pharmacist for a wider ranges of medicines, at a cheaper price. The government proposal would allow pharmacists to assess a patient, provide a consultation, and supply a treatment, similar to a GP visit. It would also mean patients get treatments at a lower cost, rather than paying full over-the-counter prices. Treatments for scabies, headlice, and conjunctivitis would be covered, as well as emergency contraception pill. Lanny Wong, a pharmacist, director of Mangawhai Pharmacy and a member of the national executive of the Pharmaceutical Society spoke to Lisa Owen.

  5:37 PM         Dr. Spencer Nadolsky and Karl sit down with Dr. Henning Langer, PhD researcher at the Charité in Berlin and founder of his own muscle metabolism lab, to break down his newly published paper combining rodent and human data to look directly at what GLP-1 medicines actually do to skeletal muscle beyond what a DEXA scan can tell you. Dr. Langer spent time at Boehringer Ingelheim specifically studying skeletal muscle during obesity and anti-obesity treatment before bringing that work to his own lab, and this paper is one of the only studies to date that has looked at muscle directly rather than lean body mass as a proxy. In this episode they cover why the step one trial's 40 percent lean mass loss figure may not be as alarming as it sounds and why most incretin trials actually land closer to the expected 25 percent, why lean body mass on a DEXA scan conflates muscle with glycogen, liver weight, and water in ways that overstate actual muscle loss, why the mice on semaglutide that looked the roughest in their cage ran the best on the treadmill to exhaustion, what mitochondrial protein changes in the proteome data suggest about a possible fatigue resistance benefit that cannot be explained by fat loss alone, how absolute muscle force tended to drop slightly while relative strength and endurance held up, what the human data from Nottingham showed about maximum voluntary contraction and knee extension force in patients on GLP-1 treatment, why the geriatric population is the next big unanswered question in this space, and why resistance training combined with high protein still cuts muscle loss in half and remains the most powerful lever available regardless of what the pharmacology does. The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we speak with Dr. Sarfaraz Niazi, Ph.D., about how biosimilar regulations have taken shape, from early FDA uncertainty to citizen petitions, lawsuits, and guideline changes. Dr. Niazi offers a behind the scene look at the way FDA policy gets made, and unmade, and his own role in key regulatory changes, and legislation such as the Biologics Price Competition and Innovations Act (BPCIA), and the Inflation Reduction Act (IRA). We also discuss Dr. Niazi's current company, RNA Therapeutics, and his quest to make new drug modalities accessible to patients around the world.     This episode of the Business of Biotech is brought to you by Cytiva. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

We're back in the saddle after Eleanor's operation and talking all about the history of Exorcism! One of those complex kinds of topic we so enjoy discussing on Magic and Medicines, belief in Exorcism is rather predicated on personal faith, including in Demons or other supernatural entities. It's also a tradition impossible to separate from the seminal movie The Exorcist of 1973 due to that film's staggering cultural impact. Thing is, Exorcism is a practice which seems to predate the written word. Almost every world religion has a version of it, with several forms of modern Paganism also embracing concepts of spirit manipulation and cleansing.So, how should we think of Exorcism as distinct from what's contained in The Exorcist?Why is it quite so popular with Catholics, and was it always?Can anybody become an Exorcist, and what protects vulnerable people from being taken advantage of by hucksters and worse? Also, should we not be thinking about Jesus and his Twelve Disciples as Exorcists, considering Exorcism is one of the things they are most celebrated for in the Gospels?Does this, in turn, mean many heroes of mystic Jewish tradition were actually the first Ghostbusters?As ever, we really hope you enjoy the episode and we will speak to you again on Thursday with our new Lang Fairy Tales episode before Saturday's release of Three Ravens Live @ Farnham Literary Festival!Three Ravens is an English Myth and Folklore podcast hosted by award-winning writers Martin Vaux and Eleanor Conlon.Released on Mondays, each weekly episode focuses on one of England's 39 historic counties, exploring the history, folklore and traditions of the area, from ghosts and mermaids to mythical monsters, half-forgotten heroes, bloody legends, and much, much more. Then, and most importantly, the pair take turns to tell a new version of an ancient story from that county - all before discussing what that tale might mean, where it might have come from, and the truths it reveals about England's hidden past...Bonus Episodes are released on Thursdays plus Local Legends episodes on Saturdays - interviews with acclaimed authors, folklorists, podcasters and historians with unique perspectives on that week's county.With a range of exclusive content on Patreon, too, including audio ghost tours, the Three Ravens Newsletter, and monthly Three Ravens Film Club episodes about folk horror films from across the decades, why not join us around the campfire and listen in?REGISTER FOR THE TALES OF SOUTHERN ENGLAND TOURVisit our website Join our Patreon Social media channels and sponsors Hosted on Acast. See acast.com/privacy for more information.

Dr. Zishan Khan, a psychiatrist at MindPath Health, joins Ian Hoch to discuss how GLP-1 medicines might not just curb your appetite, but also change what you care about.

Natalie Avalos (Assistant Professor of Native American and Indigenous Studies, University of Colorado Boulder; PhD, University of California Santa Barbara, 2015) is an ethnographer of religion whose research examines contemporary Indigenous religious life, healing historical trauma, and decolonization. A Chicana of Mexican Indigenous descent, born and raised in the Bay Area, Dr. Avalos is currently working on her manuscript, titled Decolonizing Metaphysics: Transnational Indigeneities and Religious Refusal. She served as a co-PI for a Luce Foundation-funded research group at the UC Humanities Research Institute, "Humanitarian Ethics, Religious Affinities and the Politics of Dissent." She is also the recipient of a Sacred Writes media partner fellowship to write about Buddhism and race for Religion Dispatches.  Avalos studies how Indigenous practitioners in the Denver metro area navigate the increasing use of Indigenous plant medicine like ayahuasca and psilocybin by white Americans for wellness purposes. Her informants are concerned about the metaphysical impacts of the decontextualized use of these plants, including how their commodification and increased white demand may limit Indigenous access. However, Avalos's study reveals that along with these risks are compelling possible benefits. Within their Indigenous religious context, plants are understood to have conscious, sacred intelligence revered within the larger social body. If Westerners could look through this sacred lens, plant medicines could help address human-centric biases created by colonial relations, and the West's spiritual yearning for a lost connection to the natural world. Such understanding could both benefit our ecological future and inspire rectification of historical and ongoing dispossession of Indigenous peoples. Learn more about John Templeton Foundation's Sacred Writes Working Group here: https://www.sacred-writes.org/templeton-working-group

Get ready for some vigorous shaking of bottles, because in today's episode of Magic and Medicine we're talking all about Homeopathy and Herbal Medicine!Although herbal medicine has very deep roots, stretching back to Ancient Mesopotamia, Egypt, India and China, theories about disease and its transmission have been pretty varied over time.From foul, stinking miasmas to the adorably named 'animalcules', mysterious lichen and even the humble cup of coffee, ideas about the causes of disease have certainly evolved.In the 19th century, a time of cholera epidemics, bloodletting, leeches and other sticky things, a doctor named Samuel Hahnemann began experimenting with the system he would develop into homeopathic medicine.Almost from its beginnings, homeopathy has attracted a storm of criticism - quite the backlash, in fact, for a manner of treatment which is gentle, holistic, and plant-based!Our discussion covers the history and politics of homeopathy, the memory of water, the effect of modern austerity measures on the alternative medicine community, and the many people who have sought to prove that it really is all just nonsense!Unlike Hahnemann's remedies, though, we promise this one isn't diluted...We really hope you enjoy the episode and we will speak to you again on Saturday with our new Local Legends interview with the wonderful Will Millard!Three Ravens is an English Myth and Folklore podcast hosted by award-winning writers Martin Vaux and Eleanor Conlon.Released on Mondays, each weekly episode focuses on one of England's 39 historic counties, exploring the history, folklore and traditions of the area, from ghosts and mermaids to mythical monsters, half-forgotten heroes, bloody legends, and much, much more. Then, and most importantly, the pair take turns to tell a new version of an ancient story from that county - all before discussing what that tale might mean, where it might have come from, and the truths it reveals about England's hidden past...Bonus Episodes are released on Thursdays plus Local Legends episodes on Saturdays - interviews with acclaimed authors, folklorists, podcasters and historians with unique perspectives on that week's county.With a range of exclusive content on Patreon, too, including audio ghost tours, the Three Ravens Newsletter, and monthly Three Ravens Film Club episodes about folk horror films from across the decades, why not join us around the campfire and listen in?REGISTER FOR THE TALES OF SOUTHERN ENGLAND TOURVisit our website Join our Patreon Social media channels and sponsors Hosted on Acast. See acast.com/privacy for more information.

On our penultimate County Episode of Three Ravens Series 7 we're off to the heartland of Welsh language-speaking in Merionethshire! Abolished in 1974, its flag, showing three goats rampant above the dawning sun, still flies in the area, which is filled with monuments like Harlech Castle, Tomen y Mur, some of the deepest slate mines in Wales, and a town guarded by demonic flaming cartwheels. Taking its name from the founder of the Kingdom of Gwynedd, its most famous saint founded a monastery on an island now filled with the bones of 20,000 saints. On its most famous mountain Idris the giant once watched the stars and threw loads of stones about. In its deepest lake lives Teggie, the Welsh version of the Loch Ness monster - and there's indications she actually exists!Including excerpts from this Saturday's Local Legends guest writer and broadcaster Will Millard, host of BBC's Hidden Wales, we'll talk you through it - from the strangeness of Port Merion to the shimmering wonder of the Dolgellau Gold Belt and beyond.Then we come to Martin's story for this week, "The Werewolf of Gellilydan" which is a one of a kind Victorian legend that might just unsettle you...We hope that you enjoy the episode, and will speak to you again on Thursday with our brand new episode of Magic and Medicines all about Holistic and Herbal Healing!Three Ravens is a Myth and Folklore podcast hosted by award-winning writers Martin Vaux and Eleanor Conlon.Released on Mondays, each weekly episode focuses on a historic county, exploring the heritage, folklore and traditions of the area, from ghosts and mermaids to mythical monsters, half-forgotten heroes, bloody legends, and much, much more. Then, and most importantly, we take turns to tell a new version of an ancient story from that county - all before discussing what that tale might mean, where it might have come from, and the truths it reveals about England's hidden past...Bonus Episodes are released on Thursdays plus Local Legends episodes on Saturdays - interviews with acclaimed authors, folklorists, podcasters and historians with unique perspectives on that week's county.With a range of exclusive content on Patreon too, including audio ghost tours, the Three Ravens Newsletter, and monthly Three Ravens Film Club episodes about folk horror films from across the decades, why not join us around the campfire and listen in?REGISTER FOR THE TALES OF SOUTHERN ENGLAND TOURVisit our website Join our Patreon Social media channels and sponsors Hosted on Acast. See acast.com/privacy for more information.

In the final part of this three-part episode of the Mike Drop Podcast, host Mike Ritland wraps up the conversation with former British Army sniper Ted Shirley. Ted shares his path to recovery from severe PTSD through civilian therapy, grounding techniques, EMDR, mindfulness, plant medicines, and years of hard work. He describes backpacking the world, rediscovering music, writing his book Afghanistan Sniper: Trauma on the Frontline and Beyond, giving mental health talks to veterans and military leaders, and reaching full remission—no longer carrying the diagnosis. A moving close full of hope, purpose, and the clear message that complete healing from combat trauma is possible. Learn more about your ad choices. Visit podcastchoices.com/adchoices